The outcome of Autologous Stem Cell Transplantation in First Complete Remission Acute Myeloid Leukemia Patients- Single Center Study

Post-remission treatment in patients with acute myeloid leukemia is still controversial. One potent choice for patients with no donor available is autologous stem cell transplantation. The median follow-up period was 18 months and the median age was 26 years old. In the review of 116 recently diagnosed AML patients (except AML- M3) who underwent autologous stem cell transplantation, 72.4% of patients remained alive and 27.6% relapsed. Relapse was the most common causes of death in patients. The one- year OS and DFS of patients was 73.8% and 59.8%, respectively. There was no statistically significant difference between age, sexuality and waiting time from diagnosis to transplantation. For more comprehensive results, longer follow- up is required.